Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family
- PMID: 31994352
- PMCID: PMC7196448
- DOI: 10.1002/mgg3.1151
Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family
Abstract
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmia syndrome characterized by adrenergically driven ventricular arrhythmia predominantly caused by pathogenic variants in the cardiac ryanodine receptor (RyR2). We describe a novel variant associated with cardiac arrest in a mother and daughter.
Methods: Initial sequencing of the RYR2 gene identified a novel variant (c.527G > T, p.R176L) in the index case (the mother), and her daughter. Structural analysis demonstrated the variant was located within the N-terminal domain of RyR2, likely leading to a gain-of-function effect facilitating enhanced calcium ion release. Four generation cascade genetic and clinical screening was carried out.
Results: Thirty-eight p.R176L variant carriers were identified of 94 family members with genetic testing, and 108 family members had clinical evaluations. Twelve carriers were symptomatic with previous syncope and 2 additional survivors of cardiac arrest were identified. Thirty-two had clinical features suggestive of CPVT. Of 52 noncarriers, 11 had experienced previous syncope with none exhibiting any clinical features of CPVT. A documented arrhythmic event rate of 2.89/1000 person-years across all carriers was calculated.
Conclusion: The substantial variability in phenotype and the lower than previously reported penetrance is illustrative of the importance of exploring family variants beyond first-degree relatives.
Keywords: RYR2; catecholaminergic polymorphic ventricular tachycardia; crystallography; variable expression.
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Conflict of interest statement
MT, FVP, SL, AC, KH, BF, SC, RL, SS, LA, declare no conflict of interest.
Figures





Similar articles
-
Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):748-56. doi: 10.1161/CIRCEP.112.970517. Epub 2012 Jul 10. Circ Arrhythm Electrophysiol. 2012. PMID: 22787013
-
Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.Circulation. 2002 Jul 2;106(1):69-74. doi: 10.1161/01.cir.0000020013.73106.d8. Circulation. 2002. PMID: 12093772
-
A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia.Forensic Sci Int. 2017 Jan;270:173-177. doi: 10.1016/j.forsciint.2016.12.001. Epub 2016 Dec 9. Forensic Sci Int. 2017. PMID: 27988446
-
Identification of a novel exon3 deletion of RYR2 in a family with catecholaminergic polymorphic ventricular tachycardia.Ann Noninvasive Electrocardiol. 2019 May;24(3):e12623. doi: 10.1111/anec.12623. Epub 2019 Jan 7. Ann Noninvasive Electrocardiol. 2019. PMID: 30615235 Free PMC article. Review.
-
Prognosis and clinical management of asymptomatic family members with RYR2-mediated catecholaminergic polymorphic ventricular tachycardia: a review.Cardiol Young. 2024 Jun;34(6):1182-1189. doi: 10.1017/S1047951124000714. Epub 2024 Apr 24. Cardiol Young. 2024. PMID: 38653721 Review.
Cited by
-
The link between abnormalities of calcium handling proteins and catecholaminergic polymorphic ventricular tachycardia.Tzu Chi Med J. 2021 May 14;33(4):323-331. doi: 10.4103/tcmj.tcmj_288_20. eCollection 2021 Oct-Dec. Tzu Chi Med J. 2021. PMID: 34760626 Free PMC article. Review.
References
-
- Ackerman, M. J. , Priori, S. G. , Willems, S. , Berul, C. , Brugada, R. , Calkins, H. , … Zipes, D. P. (2011). HRS/EHRA Expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 8(8), 1308–1339. 10.1016/j.hrthm.2011.05.020. - DOI - PubMed
-
- Allouis, M. , Probst, V. , Jaafar, P. , Schott, J.‐J. , & Le Marec, H. (2005). Unusual clinical presentation in a family with catecholaminergic polymorphic ventricular tachycardia due to a G14876A ryanodine receptor gene mutation. American Journal of Cardiology, 95(5), 700–702. 10.1016/j.amjcard.2004.10.057. - DOI - PubMed
-
- Amador, F. J. , Kimlicka, L. , Stathopulos, P. B. , Gasmi‐Seabrook, G. M. C. , MacLennan, D. H. , Van Petegem, F. , & Ikura, M. (2013). Type 2 ryanodine receptor domain A contains a unique and dynamic α‐helix that transitions to a β‐strand in a mutant linked with a heritable cardiomyopathy. Journal of Molecular Biology, 425(21), 4034–4046. 10.1016/j.jmb.2013.08.015. - DOI - PubMed
-
- Amador, F. J. , Liu, S. , Ishiyama, N. , Plevin, M. J. , Wilson, A. , MacLennan, D. H. , & Ikura, M. (2009). Crystal structure of type I ryanodine receptor amino‐terminal beta‐trefoil domain reveals a disease‐associated mutation “hot spot” loop. Proceedings of the National Academy of Sciences of the United States of America, 106(27), 11040–11044. 10.1073/pnas.0905186106. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical